Introduction The efficacy of pemetrexed-based chemotherapy in patients with advanced lung
adenocarcinoma with novel ROS proto-oncogene 1, receptor tyrosine kinase gene (ROS1) …

There is an ongoing debate about the relative merits of overall survival (OS) and other
metrics that can be used as primary end points in cancer clinical trials. Although survival …

The signal transducer and activator of transcription 3 (STAT3) has been suggested to play a
prominent role in mediating non–small-cell lung cancer (NSCLC) resistance to some …

Crizotinib is the first anaplastic lymphoma kinase (ALK) inhibitor to have been approved for
the treatment of non–small cell lung cancer (NSCLC) harboring an ALK fusion gene, but it …

Lung cancer carries a poor prognosis and is the most common cause of cancer-related
death worldwide. The integrin α6β4, a laminin receptor, promotes carcinoma progression in …

Alectinib is a highly selective ALK inhibitor and shows promising efficacy in non–small cell
lung cancers (NSCLC) harboring the EML4-ALK gene rearrangement. The precise …

Nintedanib (BIBF1120) is a multi-targeted angiokinase inhibitor and has been evaluated in
idiopathic pulmonary fibrosis and advanced non-small cell lung cancer (NSCLC) patients in …

Therapy of non-small cell lung cancer (NSCLC) patients has evolved over the past few years
with the incorporation of targeted therapy and immune therapy. These changes have …

Background RET fusions were recently identified in non-small cell lung cancer (NSCLC) and
are considered as a potential therapeutic target of NSCLC. Sorafenib, a multi-kinase …

Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor which has been implicated
in numerous solid and hematologic cancers. ALK mutations are reported in about 5-7% of …